Arterys, a San Francisco, California firm, won FDA clearance for its Arterys Oncology AI suite. The cleared software aids in finding lesions within CT images of the lungs (Lung AI) and in both CT and MRI when assessing the liver (Liver AI). It uses artificial intelligence methods to segment lesions and nodules, and in evaluations versus certified radiologists it performed as well as them.

The online software, accessible using a browser, allows a radiologist to measure and track the progress of tumors and suspected tumors. Because it doesn’t require any on-site infrastructure, it is inherently easy to setup and begin using, without having to manage it in the future. The application complies with HIPAA and similar privacy laws or 26 other countries, including all of Europe.

“The evaluation of primary and metastatic disease in the lung and liver are among the most valuable contributions of radiologists to the care of patients with cancer,” said radiologist and Arterys co-founder Albert Hsiao, M.D., Ph.D., in a published press release. “We desperately need more efficient technology to automatically track lung and liver lesions to further improve diagnosis, assess response to treatment, and automate reporting with standardized terminology including Lung-RADS and LI-RADS. The Oncology Lung AI and Liver AI products are designed to maximize efficiency and accuracy of the radiologist read and will power next-generation radiology interpretation.”